Abstract: Linezolid (trade names Zyvox™ , Zyvoxid™ and Zyvoxam™) is a synthetic antimicrobial agent of the family of oxazolidinones, which has been approved for the treatment of vancomycin-resistant Enterococcus faecium infections, lower respiratory tract infections, skin and skin-structure infections and diabetic foot infections caused by susceptible bacteria. Its antimicrobial spectrum, which includes Gram-positive cocci and bacteria resistant to other antimicrobials, its favorable pharmacokinetic properties and its safety profile make it an important addition to our therapeutic armamentarium. In this review, we summarize the literature describing linezolid's in vitro characteristics, the clinical experience regarding its approved and off-label clinical uses and its safety and tolerability.
Introduction
Oxazolidinones are synthetic antibacterial agents first developed by DuPont Pharmaceuticals in the late 1970s for use in agriculture. By the mid-1980s, more oxazolidinone derivatives potentially useful for human use were released but the early analogues (DuP 105 and DuP 721) proved unsuitable for pharmaceutical development. 1 Investigation was re-initiated by the Upjohn Corporation in the early 1990s, leading to the discovery of linezolid (U-100766), which had promising in vitro and pharmacokinetic properties. Linezolid (trade names Zyvox™, Zyvoxid™ and Zyvoxam™) was the first oxazolidinone to enter into the market in 2000 in the USA by Amersham Pharmacia (now Pfizer) and subsequently it was approved for use in Europe and in Asia. This represented a landmark in antimicrobial research with linezolid being the first truly novel antibiotic to become approved for clinical use since 1972.
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This review outlines linezolid's mechanism of action, in vitro antimicrobial activity and pharmacokinetic properties. Also acquired resistance mechanisms developed by certain bacterial species against linezolid are discussed and current clinical experience from its use is summarized in order to define its current place in our armamentarium in the battle against infection.
Mechanism of Action
Linezolid binds to the 23S rRNA of the 50S subunit of the prokaryotic ribosome, preventing it from complexing with the 30S subunit, mRNA, initiation factors and N-formylmethionyl-tRNA. 4, 5 Recent elegant studies using X-ray crystallography have determined the crystal structure of linezolid and have elucidated the binding site of the drug on the peptidyltransferase center of the large ribosomal subunit. This site overlaps significantly with the aminoacyl moiety of bound tRNA and stabilizes a distinct conformation of nucleotide U2585. 6 The net result is to block assembly of a functional initiation complex for protein synthesis, thereby preventing translation of the mRNA. This mode of action differs from that of older protein synthesis inhibitors such as chloramphenicol, macrolides, lincosamides and tetracyclines, which allow mRNA translation to begin but then inhibit peptide elongation. This difference is significant in two respects. First, linezolid seems particularly effective in preventing the synthesis of staphylococcal and streptococcal virulence factors (e.g. coagulase, haemolysins, leucocidins, protein A, streptolysin O and DNAase). 7 Second, linezolid has a target that does not overlap with those of other protein synthesis inhibitors; consequently, no cross-resistance with drugs of other classes is exhibited. 8 
In Vitro Antimicrobial Activity
Linezolid demonstrates in vitro activity against most Gram-positive aerobes including Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus spp., and Enterococcus spp. Its activity is maintained irrespective of resistance to other drugs as a consequence of the unique mode of its antimicrobial action. Thus, linezolid is equally active against methicillin-susceptible and -resistant staphylococci including vancomycin-intermediate strains, against vancomycin-susceptible enterococci and those with VanA, VanB or VanC determinants and against pneumococci susceptible or resistant to penicillins and/or macrolides.
Numerous in vitro studies have shown that linezolid has narrow, unimodal MIC distributions. The MICs for enterococci, pneumococci, staphylococci and streptococci fall between 0.5 and 4 µg/ml. MIC 90s were usually 1 to 2 µg/ml. [9] [10] [11] [12] [13] Linezolid has also demonstrated potency against viridans group streptococci, Clostridium perfringens, Clostridium difficile, Nocardia spp., Bacillus spp., Corynebacterium spp., Listeria monocytogenes, Erysipelothrix rhusiopathiae, Leuconostoc spp., Pediococcus spp., and Rhodococcus equi. For each of these species or species groups, the strains tested were inhibited by =4 µg/ml of linezolid.
14 Most Gram-negative organisms are inherently resistant to linezolid (see section on mechanisms of resistance), but MICs of 4-8 µg/ml are seen for many Bacteroides spp., Moraxella catarrhalis and Pasteurella spp. 15 Linezolid has shown in vitro activity against Mycobacteria including M. avium complex and M. bovis. It is active against Mycobacterium tuberculosis irrespective of resistance to other antimicrobial classes. MIC 90s of 1 to 8 mg/ml have been reported for 39 MDR M. tuberculosis clinical strains. 16 Susceptibility interpretive criteria proposed by CLSI 17 and EUCAST 18 are shown in Table 1 .
Linezolid is essentially bacteriostatic, achieving less than a 2 log 10 reduction in the count of enterococci and staphylococci over 24 h when tested at 4 × MIC. One group observed a 3-4 log 10 reduction in bacterial count over 6 h for pneumococci, and concluded that linezolid was bactericidal against these organisms; 15 another found little or no bactericidal activity for linezolid against viridans or β-haemolytic streptococci. 19 Bactericidal in vitro activity was also observed against Bacteroides fragilis and C. perfringens.
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Metabolism, Pharmacokinetic/ Pharmacodynamic Properties
The pharmacokinetics of linezolid have been extensively studied as part of the clinical development of the agent. Therefore, there is available data from healthy volunteers and patients with stable excretory organ failure as well as from special patient groups.
Linezolid may be assayed in body fluids by HPLC. Available formulations of the agent include an intravenous (iv) form, film-coated tablets and an oral suspension. The recommended dose is 600 mg b.i.d.
Linezolid is well absorbed with a mean absolute bioavailability of ∼100% in healthy volunteers. Major pharmacokinetic parameters after multiple i.v or oral doses are shown in Table 2 .
The volume of distribution at steady state in healthy adults is 30-50 L. Protein binding is 31% and is not concentration dependent. Adequate to good tissue penetration into skin blister fluids, bone, muscle, fat, alveolar cells, lung extracellular lining fluid and CSF has been documented. In healthy volunteers penetration into cantharidine-induced skin blisters was 104% ± 21% (range 80%-130%) compared with serum. 20 Plasma and lung epithelial lining fluid concentrations were 15.5 ± 24.2 and 64.3 ± 33.1 µg/ml at 4 h and 10.2 ± 2.3 and 24.3 ± 13.3 µg/ml at 12 h, respectively, after multiple oral doses in healthy volunteers. Concentrations in alveolar cells were much lower, with a mean Cmax of 2.2 ± 0.6 µg/ml at 4 h. The mean fluid to plasma ratios for sweat and saliva were 0.55:1 and 1.2:1, respectively 21 and bone, fat and muscle penetration was shown to be at the level of 60%, 37% and 94% of plasma concentration, respectively. 22 In a patient with meningitis, administration of iv linezolid 600 mg b.i.d. produced adequate CSF penetration, with a CSF:plasma ratio of 0.8. On day 5 of treatment CSF levels were 5.36 µg/ml and 3.8 µg/ml, at 5 and 12 h after infusion. 23 In patients with ventricular-peritoneal shunts and noninflamed meninges, the ratio of CSF:plasma concentration was 0.7:1.0 after multiple linezolid doses. 21 Linezolid is primarily metabolized by nonenzymatic oxidation that produces two major metabolites (PNU-142300 and PNU-142586) and numerous minor ones. None of these has any antibacterial activity. Involvement of the cytochrome P450 (CYP) system in the metabolism of linezolid has not been demonstrated and linezolid neither induces nor inhibits human CYP isoforms.
Drug elimination takes place by renal and nonrenal routes. Overall, non-renal clearance is 65% of the total clearance of linezolid.
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The pharmacokinetics of linezolid are age dependent, with infants and children having greater plasma clearance, larger volumes of distribution and corresponding lower serum concentrations and serum AUC. 24 In children, administration of linezolid 10 mg/kg three times daily is required.
No differences were noted between groups of men and women but pharmacokinetic studies have not been performed to date in patients of extreme old age. Nevertheless, dose adjustment in old age is not recommended. 25 Lower but presumably adequate serum levels were observed in obese patients. 26 Linezolid pharmacokinetics have been studied in patients with mild to moderate liver disease. No statistically significant differences were observed compared with healthy volunteers so no dose modification is recommended in mild to moderate hepatic insufficiency. There are no studies in severe hepatic failure (i.e. Child-Pugh Class C), but as linezolid is metabolized predominantly by a non-enzymic process, impairment of hepatic function would not be expected to alter the pharmacokinetics significantly. 21 Linezolid pharmacokinetics have been studied in patients with varying degrees of renal insufficiency and no significant differences were noted. Haemodialysis removed 30% of the linezolid dose. Thus, administration of the standard dosage of linezolid, 600 mg every 12 h, is recommended irrespective of the degree of renal insufficiency and should be scheduled after haemodialysis. 27 Also, penetration of linezolid has been studied into inflamed areas of diabetic foot infection. Tissue/ plasma ratios of mean 101.7% produced a mean concentration of 9.6 µg/g, which is greater than those predicted to be effective against MRSA. 28 The pharmacodynamic characteristics of linezolid have been studied both in animal models and in human studies; T  MIC or AUC 24  MIC were found to be the most accurate predictors of in vivo efficacy.
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Mechanisms of Resistance
Early in vitro studies have shown that mutational linezolid resistance is extremely difficult to select in vitro against Gram-positive cocci. 8, 15 When resistance was ultimately obtained by in vitro passage of staphylococci and enterococci, it was found to be associated with target site mutations to the central loop of domain V of the 23S rRNA, which lies in the 50S ribosomal subunit. Multiple 23S rRNA copies of the genes are present in most species and more than one of these must be altered for resistance to arise, perhaps explaining the difficulty of selection.
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Despite the difficulty of in vitro selection, linezolid resistance has emerged during therapy first in enterococci and S. aureus and more recently in coagulasenegative staphylococci. Low dose, indwelling lines and devices, protracted therapy and sequestered sites of infection have been identified as risk factors for resistance development. 31, 32 Acquired resistance in clinical isolates has been associated with a G2576T mutation in at least two gene copies encoding for 23S rRNA. The MIC level correlates with the number of mutated gene copies. 33 Linezolid-resistant enterococci have emerged sporadically during treatment 31, 34 but also as a result of horizontal dissemination among hospitalized patients, irrespective of linezolid exposure. [35] [36] [37] [38] Linezolid resistance in S. aureus was first described in a sporadic strain in 2001 39 and remains rare. 40 Additionaly to the G2576T mutation, a T2500A mutation in domain V of the 23S rRNA gene and loss of a single copy of the 23S rRNA gene have been identified in a linezolid-resistant S. aureus clinical isolate. 41 Recently, nosocomial outbreaks of linezolid-resistant S. epidermidis have been described in various institutions 42, 43 and the underlying mechanism of resistance was a G2576T mutation 42 or a G2603T mutation 44 or a T2504A mutation 45 in the 23S rRNA gene. Unfortunately, oxazolidinone resistance mechanisms are not limited to 23S rRNA mutations. Methylation of 23S rRNA (A2503) by the horizontally transmitted Cfr methyltransferase has been described to confer resistance to linezolid as well as phenicols, lincosamides, pleuromutilins, and streptogramin A. 46 Also, ribosomal protein L3 mutations have been identified in S. aureus clinical isolates. 47 Linezolid resistance in S. pneumoniae is extremely rare and has been associated with a deletion in the gene encoding ribosomal protein L4. 48 The ribosomes of Escherichia coli are as susceptible to linezolid as those of Gram-positive cocci but, with minor exceptions (see spectrum of activity), Gram-negative bacteria are oxazolidinone resistant most likely because oxazolidinones are excreted by an endogenous AcrAB efflux pump. 50 In the most recent 2008 ZAAPS report, among 6121, eight linezolid-resistant isolates were detected in 7 countries among the enterococci (E. faecalis [3] and E. faecium [2] ) and CoNS (3 S. epidermidis). Gram-positive clinical isolates 99.5% were susceptible.
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Clinical Studies
Linezolid has been approved for the treatment of vancomycin-resistant Enterococcus faecium infections including bacteremia, nosocomial pneumonia caused by methicillin-resistant (MRSA) or methicillin-susceptible S. aureus (MSSA), complicated or uncomplicated skin and skin-structure infections and diabetic foot infections without osteomyelitis (in USA only) caused by susceptible bacteria, and community-acquired pneumonia caused by S. aureus or S. pneumoniae. Linezolid is the first agent approved to treat infections caused by MRSA in 140 years and the second agent (and first oral agent) approved to treat infections caused by vancomycin-resistant enterococci.
Clinical studies supporting these approved indications as well as studies describing existing clinical experience on off-label indications will be reviewed.
Skin and Skin-structure Infections (SSSIs)
A summary of relevant randomized comparatorcontrolled clinical trials (RCT) is depicted in Table 3 . Most of these studies have shown non-inferiority of linezolid compared to antistaphylococcal penicillins or most frequently to vancomycin although some studies have shown superiority of linezolid especially in MRSA eradication.
57,60,63
A meta-analysis 65 of eight randomized controlled trials that reported data on SSSIs revealed that empirical treatment with linezolid was associated with significantly better success than glycopeptides or β-lactams in clinically assessed patients (2,350 clinically assessed patients, OR 1.65 [1.08 to 2.53]). The odds ratio for linezolid superiority was 2.24 (95% CI 1.12 to 4.48) against glycopeptides and 1.37 (95% CI 1.00 to 1.88) against β-lactams. Another recent meta-analysis evaluating six randomized controlled trials of linezolid versus vancomycin for SSSIs concluded that success of empirical treatment was achieved in 89% of linezolid-treated patients and in 86% of vancomycin-treated patients. Empirical treatment of patients with SSSIs with linezolid was associated with significantly better success than vancomycin (1438 clinically assessed patients, OR 1.40, 95% CI 1.01 to 1.95). 66 Finally a meta-analysis evaluating four randomized clinical trials of linezolid versus vancomycin for MRSA hospital-acquired SSSIs was not able to detect a statistically significant difference between the two treatments. 67 In the study by Wiegelt et al, 57 the mean total duration of treatment was similar in both groups but the mean duration of i.v. treatment was significantly shorter for patients who received linezolid than for those who received vancomycin (4.7 and 11.1 days, respectively; P = 0.0001). In another study by Wiegelt et al, 60 the overall mean duration of treatment was longer for patients receiving linezolid (11.8 ± 4.9 vs. 10.9 ± 5.3 days) but i.v. duration was significantly shorter (4.0 ± 2.6 vs. 9.0 ± 5.3 days).
Itani et al 68 compared the health outcomes (other than clinical efficacy and safety) of patients randomized to receive linezolid or vancomycin for cSSSIs in the previously mentioned study by Wiegelt et al. 60 Linezolid treatment was associated with significantly shorter length of stay (all P  0.01), decreased i.v. antibiotic treatment duration (all P  0.0001) and higher discharge rates the first 2 weeks after start of treatment (all P  0.05). The authors concluded that linezolid has the potential to reduce medical resource use for the treatment of cSSSIs. Cost effectiveness studies have shown linezolid treatment to be costeffective for patients with c-SSSIs when MRSA is a probable cause.
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Pneumonia
RCTs evaluating linezolid in comparison with a glycopeptide or a b-lactam for the treatment of pneumonia are summarized in Table 4 .
Two retrospective analyses of data from two prospective RCTs for nosocomial pneumonia 70, 72 concluded that in the subset of patients with MRSA 75 and in the subset of patients with MRSA ventilator-associated pneumonia, linezolid treatment was an independent predictor of survival (OR 4.6, 95% CI, 1.5 to 14.8, P = 0.01) and clinical cure (OR 20.0, 95% CI, 4.3 to 92, P  0.001). 76 The superior efficacy of linezolid was attributed to its good intrapulmonary penetration (see pharmacokinetics above). There is only one RCT designed specifically to study the efficacy of linezolid in MRSA pneumonia 74 but it was limited by a very small number of patients and did not confirm linezolid's superiority ( Table 4 ). The use of linezolid for the treatment of nosocomial pneumonia caused by MRSA was found to be cost-neutral compared with vancomycin because it can be given orally reducing hospital stay (Mullins).
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A meta-analysis of seven RCTs evaluated the efficacy of linezolid in comparison to that of vancomycin or b-lactams for the treatment of lower respiratory tract infections. There was no difference in success rates of empirical treatment for pneumonia ( 
Bacteremia
There is only one RCT designed specifically to study the efficacy of linezolid in bacteremia. 78 Data from this study as well as from studies, which included primary of secondary bacteremias and CRBIs among other types of infections, are shown in Table 5 .
A retrospective analysis of case series of patients who received linezolid as salvage therapy for persistent MRSA bacteremia found that the early microbiological response (i.e. negative results for follow-up blood culture within 72 hours) was significantly higher in the linezolid-based salvage therapy group than the comparison group (75% vs. 17%; P = 0.006). Adding aminoglycosides or rifampicin to vancomycin was not successful in treating any of the patients, whereas linezolid-based therapy gave an 88% salvage success rate (P  0 .001).
The S. aureus-related mortality rate was lower for patients treated with a linezolid salvage regimen than for patients continually treated with a vancomycinbased regimen (13% vs. 53%; P = 0.030).
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Another retrospective study evaluated patients treated with linezolid (n = 68) or daptomycin (n = 30) for VRE bacteremia. Univariate analyses showed no significant differences between the groups regarding baseline demographic and clinical characteristics, severity of illness and co-morbidity. Daptomycin was associated with a trend towards a higher mortality rate (26.7% vs. 20.6%), longer median duration of bacteremia (3 vs. 2 days) and higher relapse rate (6.7% vs. 2.9%), but these differences did not reach statistical significance (P  0.2). Microbiological cure rates were 90% for the daptomycin group and 88.2% for the linezolid group (P = 0.92).
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A pooled analysis of five prospective, RCTs demonstrated that linezolid is associated with outcomes that are not inferior to those of vancomycin in 144 patients with S. aureus bacteraemia (53 patients with MRSA). There were no differences between treatment groups in clinical outcome, in microbiological outcome and in survival. 81 In a meta-analysis of 12 RCTs involving 6093 patients, the efficacy of linezolid was compared with glycopeptides or β-lactams. Five RCTs reported outcomes for patients with bacteremia. Overall success of empirical treatment was achieved in 81.3% of linezolidtreated patients and in 66.4% of patients treated with other antibiotics. Empirical treatment with linezolid was associated with better success than glycopeptides or β-lactams (255 clinically assessed patients; OR 2.07, 95% CI 1.13 to 3.78). 65 However, the isolated pathogens were different, their absolute number was small, most of the data came from non-blinded RCTs not allowing any meaningful comparison for the treatment of specific pathogens. Therefore, the authors could not reach any definitive conclusions about the effectiveness of linezolid for the treatment of bacteraemic patients. A recent meta-analysis of RCTs evaluating the efficacy of linezolid and vancomycin in the treatment of various Gram-positive infections included three trials that reported outcomes for patients with bacteremia. Success of empirical treatment was achieved in 76% of linezolid-treated patients and in 78% of vancomycin-treated patients. There was no significant difference in treatment success for bacteremia between linezolid and vancomycin (271 clinically assessed patients, OR 0.88, 95% CI 0.49 to1.58).
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Endocarditis
Although linezolid is a bacteriostatic antibiotic, it has been administered in patients with bacterial endocarditis when failure or intolerance to first line regimens had limited the therapeutic options. Relevant experience has been published in the form of case reports and case series studies and has been reviewed by Falagas et al 82 and Munoz et al. 83 Results from published case series are included in Table 6 . At present, linezolid is not a standard therapy for endocarditis, although guidelines published by the American Heart Association consider it to be a reasonable alternative for cases of endocarditis caused by multiresistant enterococci. 86 
Central Nervous System Infections (CNS)
Linezolid has been used for the treatment of CNS infections caused by multidrug resistant Grampositive pathogens because of its adequate CSF penetration. Published case reports were reviewed by Ntziora et al. 87 In most of the reported cases, failure of first line treatment regimens or intolerance to them were the reasons for linezolid use. Overall a success rate of 90.5% was reported for a variety of pathogens (mainly penicillin-non-susceptible S. pneumoniae, VRE, Nocardia spp and methicillin-resistant staphylococci) and a variety of clinical situations. Currently, linezolid is recommended by the Infectious Diseases Society of America as an alternative for the treatment of methicillin-resistant staphylococcal or vancomycin-resistant enterococcal meningitis (rated B-III).
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Bone and Joint Infections (BJI)
The available literature of BJIs consists of case reports and case series studies. A summary of published case series studies is presented in Table 7 . Failure or intolerance of first line antimicrobials or isolation of resistant bacteria were the reasons for linezolid use in all of these reports.
In a retrospective case-control study by Papadopoulos et al 99 the efficacy of linezolid for a variety of bone infections with and without prosthetic material was compared to that of various combination regimens commonly used in that institution. Treatment duration was shorter in the linezolid group (6 vs. 20 weeks, P = 0.001). There was no statistically significant difference in efficacy at the end of treatment between the two groups but there was a significantly higher relapse rate in the linezolid arm (38% vs. 4%, P  0.001). Overall, the clinical efficacy of linezolid in these case series, which comprised very heterogeneous groups of patients, ranged from 55%-100%. Prospective controlled studies are warranted although there are concerns about potential side effects of long-term use of linezolid in that setting (see section on safety).
Neutropenic Patients
Although linezolid is a bacteriostatic agent it has been evaluated in neutropenic patients for the treatment of Gram-positive bacterial infections. Results from published clinical trials are presented in Table 8 . There is only one published RCT, which showed that linezolid was equivalent to vancomycin in terms of clinical efficacy and safety for the treatment of Grampositive infections in febrile neutropenic patients. Time to defervescence was shorter in linezolid group although post hoc analyses revealed delayed recovery of absolute neutrophil counts for linezolid-treated patients. Mortality was comparable in the two groups but linezolid was associated with fewer drug-related adverse events and fewer cases of drug-related renal failure.
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Tuberculosis
Recent small case series have reported clinical and radiographic improvement among patients with intractable multi-drug or extensively-drug resistant tuberculosis (MDR/XDR-TB) whose treatment regimens included linezolid. Park et al prescribed linezolid (600 mg bid for 14 days and then 600 mg/day) for 3-18 months (in addition to 4 more drugs) in 8 patients with XDR or MDR TB and conversion was noted in all patients after 82 ± 47 days. Only one patient developed reversible anemia but four patients developed peripheral neuropathy and two patients optic neuropathy. 103 Koh et al evaluated a dose of 300 mg in 24 patients with MDR/XDR TB and reported that 92% converted after a median of 89 days. Mean duration of linezolid therapy was 359 days and four patients developed peripheral neuropathy but none had hematological side effects. 104 Condos et al reported on seven patients who received linezolid (600 mg bid) for a period of 9-26 months with conversion of 85.7% of them. Two patients developed peripheral neuropathy. 105 von der Lippe et al reported a cohort of ten patients with MDR-TB, seven of whom developed significant side effects necessitating discontinuation Table 7 . Case series studies on the use of linezolid (600 mg bid po or iv) for the treatment of patients with bone or joint infections. of linezolid. 106 In a larger series, 30 patients received a dose of 600 mg for 8-36 months and 73% of them completed treatment with a successful outcome. Six patients developed peripheral or optic neuropathy. 107 Recently, Migliori et al 108 reported 85 patients with MDR/ XDR-TB who were treated with linezolid 600 mg bid or qd. Thirty-two percent required discontinuation of treatment because of side effects. Discontinuation was significantly more frequent among patients receiving the 600-mg bid. Twice-daily administration produced more major side-effects than once-daily dosing, with no difference in efficacy found. The authors concluded that linezolid 600 mg q.d. added to an individualized multidrug regimen may improve the chance of bacteriological conversion, providing a better chance of treatment success in only the most complicated MDR/XDR-TB cases. Its safety profile does not warrant use in cases for which there are other, safer, alternatives.
Study design
Type of infection
Safety
The safety of linezolid in adults has been studied in seven comparator-controlled phase 3 clinical trials. 109 Data on the tolerability of linezolid were obtained in 2,046 patients and compared to 2,001 comparator drug-treated patients. Drug-related adverse events were reported for 444 (21.7%) of linezolid-treated patients and for 314 (15.7%) of comparator-treated patients (P = 0.001), although drug discontinuation due to adverse events was reported for 2.4% and 1.9% of patients, respectively (P = 0.23). Also, there was no statistically significant difference in the percentage of patients who exhibited serious drugrelated adverse events or in the mortality among those two groups. The most common drug-related adverse events associated with both linezolid and comparator agents were diarrhea (4.3 and 3.2%, respectively; P = 0.074), nausea (3.4 and 2.3%, respectively; P = 0.036), and headache (2.2 and 1.3%, respectively; P = 0.047).
Abnormalities in hematologic parameters were comparable between linezolid and the comparators. The proportion of patients who developed substantially abnormal hematological values was not statistically significant between the two groups although longer treatment durations (14 days) were associated with Table 8 . Clinical studies evaluating the efficacy of linezolid in cancer patients.
Study design
a small increase in the risk for lower platelet counts in linezolid-treated patients.
The incidence of linezolid-induced thrombocytopenia was estimated to be 2.4% from the original trials. 110 Nevertheless, other studies have reported rates from 7.5% 84 to 48%. 111 Risk factors for thrombocytopenia besides long treatment duration (10 days) were lower platelet counts at baseline, 112 renal insufficiency 113 and hematologic malignancies. 101 The incidence of anemia was reported to be 5.4%. 110 In a case control study the onset of anemia was 7.4 weeks after initiation of therapy and predictive factors for this adverse event were age  58 years and low pretreatment hemoglobin values. 95 Increased susceptibility to anemia was also demonstrated in patients with renal insufficiency.
113 Leucopenia was a rare adverse event occurring in 3.3% of patients in phase III clinical trials and it was fully reversible. 114 Pancytopenia has also very rarely been reported. 115 All hematological adverse events were reversible after drug discontinuation. Weekly evaluation of hematological parameters is advised for all patients receiving 14 days of linezolid treatment.
The postmarketing experience enhanced knowledge about the drug's safety. Lactic acidosis, convulsions, optic and peripheral neuropathy have been reported.
Case reports of peripheral neuropathy include stocking-like and glove-like sensory neuropathy. Optic neuropathy symptoms include loss of color perception, blurred vision and progressive visual loss. Thirty-five cases of peripheral neuropathy, nine cases of toxic optic neuropathy and five cases of combined neuropathy have been reported. Most patients were treated for longer than 28 days. 116 Bell's palsy has also been reported in one patient receiving linezolid for 23 days. 117 After the drug's discontinuation, optic neuropathy was fully or partially reversible after 5 to 9 months 118 and complete resolution of Bell's palsy occurred after 3 months. 117 On the contrary, peripheral neuropathy was only partially reversible. 119 Lactic acidosis, attributed to linezolid, has been reported in case reports. 119 It is correlated with prolonged treatment, but it was also reported in patients receiving shorter courses of linezolid (1-16 weeks, median 6 weeks). 119, 120 Immediate discontinuation of linezolid is recommended usually leading to resolution of hyperlactatemia within 2 weeks (range, 3 days 2 weeks); nevertheless, three fatalities were reported. 119 Patients receiving linezolid should be monitored for signs and symptoms of hyperlactatemia (nausea, vomiting, mental status changes, tachycardia, hypotension) and for the serum level of bicarbonate.
Linezolid is a weak reversible monoamine oxidase (MAO) inhibitor and has the potential to interact with adrenergic and serotonergic agents. In Phase III studies, 30% of linezolid-treated patients and controls received agents that could interact with MAO inhibitors. In these patients, adverse events were generally mild to moderate, with a low overall incidence and similar rates in both linezolid and comparator groups. Hypertension was reported in 0.3% of the linezolid group and in 0.2% of the comparator group. 109 After the drug was approved and marketed several reports documented serotonin syndrome (cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination) in association with concomitant use of linezolid and serotonin agonists mostly selective serotonin reuptake inhibitors (SSRI). 121, 122 Onset of symptoms occurred 1-28 days after initiation of linezolid and most of the cases resolved in 1-9 days after drug discontinuation. Three deaths were reported to be associated with the syndrome. 119, 122 In one retrospective survey, the frequency of linezolid-induced serotonin syndrome was less than 3%. 123 Recommendations have been made for a washout period of discontinuing SSRI drugs before linezolid can be administered. 119 FDA released a safety report stating that patients with carcinoid syndrome or patients receiving SSRIs, tricyclic antidepressants, serotonin 5-HT1 receptor agonists, meperidine or buspirone should be monitored for serotonin syndrome symptoms and signs and if this is not possible, linezolid should not be administered.
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Place in Therapy
Linezolid has offered some important advantages in our therapeutics against serious infections. Its antibacterial spectrum extending to Gram-positive pathogens resistant to one or many classes of antimicrobials, its pharmacokinetic properties characterized by intravenous and excellent oral bioavailability providing opportunity for early oral switch and discharge of the patient as well as no need for dose adjustment in any patient population and its clinical efficacy which is not inferior to studied comparators for a variety of approved clinical indications and even superior to them for skin and skin-structure infections include some of the major advantages offered by this antimicrobial. Linezolid has been proved easily tolerated by patients and safe in clinical trials although close follow-up is necessary for the possibility of hematological toxicity and especially for neurological toxicity and disturbances of acid-base homeostasis with longterm use beyond approved indications. Bacteriostatic in vitro activity could be a limitation for use in infections thought to require killing antimicrobial activity such as endocarditis. Emerging acquired resistance to linezolid in enterococci and staphylococci mandates for caution and wise use in clinical practice.
In the era of antimicrobial resistance development even in community-acquired infections, a fearful example being CA-MRSA, linezolid becomes an important option for treatment of serious infections caused by Gram-positives, including vancomycin-non susceptible staphylococci and vancomycin-resistant enterococci.
